Yan Peng, M.D., Ph.D.

Harold C. Simmons Comprehensive Cancer Center

Pathology
Breast Pathology
Gynecologic Pathology

Biography

Dr. Yan Peng completed her Pediatric Residency/Chief Resident at Beijing Medical University Hospitals and practiced there as a Pediatric Nephrologist for two years. After a combined six years of basic research on kidney disease at Mayo Clinic, Rochester, MN and UT Southwestern Medical Center (UTSW), Dallas, TX, she went to University of Pittsburgh Medical Center (UPMC) for her Pathology Residency. Upon the completion, she took two fellowship trainings in Breast and Gynecologic Pathology at UPMC and Cytopathology at Beth Israel Deaconess Medical Center and Harvard Medical School in Boston, respectively.

She has been a Breast and Gynecologic Pathologist and Cytopathologist at UT Southwestern Medical Center. She is the Pathology Liaison at Cancer Committee of UTSW Simmons Cancer Center and University Hospital. She had served as Medical Directors of Diagnostic Immunohistochemistry Laboratory and Tumor Biomarker Image Analysis Laboratory at one of UTSW teaching hospitals for 10 years. As co-investigator, she has participated in more than 30 National Cancer Institute (NCI) Breast and Gynecologic cancer clinical trials.

She has published 70 peer-reviewed articles and served as an editorial board member for multiple scientific journals.

Education & Training

Graduate School - Beijing Medical University, China (1989-1991)
Fellowship - UT Southwestern Medical Center (1995-1999), Molecular Nephrology Research
Other Post Graduate Training - Beijing Medical University, China (1989-1991)
Medical School - Beijing Medical University (1980-1986)
Fellowship - Mayo Clinic College of Medicine (1993-1995), Physiology
Residency - Beijing University Hospital (1986-1989), Pediatrics
Residency - University of Pittsburgh Medical Center (1999-2003), Anatomic & Clinical Pathology
Fellowship - University of Pittsburgh Medical Center Magee Womens Hospital (2003-2004), Breast & Gynecologic Pathology
Fellowship - Harvard Medical School/Beth Israel Deaconess Medical Center (2004-2005), Cytopathology

Honors & Awards

Distinguished Young Investigator Award in Medicine 1993, Beijing, China
Distinguished Scientist Award of Canada China Child Health Foundation 1992
Member, UT Southwestern Medical School Deans Standing Committee (Faculty Council) 2017-2019
Best National Medical Article Award 1991, China
President, International Association of Chinese Pathologists (IACP) 2017-2018
Member, Abstract Review Board of United States and Canadian Academy of Pathology (Breast Pathology Category) 2017-2020
President, UT Southwestern Faculty Senate 2017-2018
Chair, Pathology Faculty Mentoring Committee 2017
Member, Faculty Promotion and Tenure Committee for UT Southwestern Medical School 2018
President, North Texas Society of Pathologists (NTSP) 2017-2018

Books & Publications

Books
- Invasive Breast Carcinomas in Peng Y, Kong C, and Chen Y. Practical Breast Pathology. Atkins K and Kong C (eds.), a volume in the Pattern Recognition Series. Kevin O. Leslie and Mark R.Wick (eds.).
  Peng Y, Kong C, and Chen Y. (2013; 147-212), Philadelphia, PA, Elsevier
Publications
- SAP30 promotes breast tumor progression by bridging the transcriptional corepressor SIN3 complex and MLL1.
  Bao L, Kumar A, Zhu M, Peng Y, Xing C, Wang JE, Wang Y, Luo W, The Journal of clinical investigation 2023 Sep 133 17
- Nuclear staining for pan-Trk by immunohistochemistry is highly specific for secretory carcinoma of breast: pan-Trk in various subtypes of breast carcinoma.
  Ye Q, Chen H, Han C, Peng Y, Huang X, Sun H, Wu Y, Albarracin CT, Middleton LP, Sahin AA, Huo L, Ding Q, Journal of clinical pathology 2023 Aug
- HER2 in uterine serous carcinoma: Current state and clinical perspectives.
  Navarro Sanchez JM, Finkelman BS, Turner BM, Katerji H, Wang X, Varghese S, Wang T, Peng Y, Hicks DG, Zhang H, American journal of clinical pathology 2023 Jun
- Limiting mitochondrial plasticity by targeting DRP1 induces metabolic reprogramming and reduces breast cancer brain metastases.
  Parida PK, Marquez-Palencia M, Ghosh S, Khandelwal N, Kim K, Nair V, Liu XZ, Vu HS, Zacharias LG, Gonzalez-Ericsson PI, Sanders ME, Mobley BC, McDonald JG, Lemoff A, Peng Y, Lewis C, Vale G, Halberg N, Arteaga CL, Hanker AB, DeBerardinis RJ, Malladi S, Nature cancer 2023 Jun 4 6 893-907
- Targeting CXCL16 and STAT1 augments immune checkpoint blockade therapy in triple-negative breast cancer.
  Palakurthi B, Fross SR, Guldner IH, Aleksandrovic E, Liu X, Martino AK, Wang Q, Neff RA, Golomb SM, Lewis C, Peng Y, Howe EN, Zhang S, Nature communications 2023 Apr 14 1 2109
- TRPS1 and GATA3 Expression in Invasive Breast Carcinoma With Apocrine Differentiation.
  Wang J, Peng Y, Sun H, Aung PP, Resetkova E, Yam C, Sahin AA, Huo L, Ding Q, Archives of pathology & laboratory medicine 2023 Apr
- Current Biological, Pathological and Clinical Landscape of HER2-Low Breast Cancer.
  Zhang H, Peng Y, Cancers 2022 Dec 15 1
- HER2-low breast cancers: Current insights and future directions.
  Zhang H, Karakas C, Tyburski H, Turner BM, Peng Y, Wang X, Katerji H, Schiffhauer L, Hicks DG, Seminars in diagnostic pathology 2022 Jul
- Update on prognostic and predictive biomarkers of breast cancer.
  Hou Y, Peng Y, Li Z, Seminars in diagnostic pathology 2022 Jun
- Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress.
  Liu X, Viswanadhapalli S, Kumar S, Lee TK, Moore A, Ma S, Chen L, Hsieh M, Li M, Sareddy GR, Parra K, Blatt EB, Reese TC, Zhao Y, Chang A, Yan H, Xu Z, Pratap UP, Liu Z, Roggero CM, Tan Z, Weintraub ST, Peng Y, Tekmal RR, Arteaga CL, Lippincott-Schwartz J, Vadlamudi RK, Ahn JM, Raj GV, Nature cancer 2022 Jun
- Metabolic diversity within breast cancer brain-tropic cells determines metastatic fitness.
  Parida PK, Marquez-Palencia M, Nair V, Kaushik AK, Kim K, Sudderth J, Quesada-Diaz E, Cajigas A, Vemireddy V, Gonzalez-Ericsson PI, Sanders ME, Mobley BC, Huffman K, Sahoo S, Alluri P, Lewis C, Peng Y, Bachoo RM, Arteaga CL, Hanker AB, DeBerardinis RJ, Malladi S, Cell metabolism 2022 Jan 34 1 90-105.e7
- The Role of Breast Cancer Stem Cells in Chemoresistance and Metastasis in Triple-Negative Breast Cancer.
  He L, Wick N, Germans SK, Peng Y, Cancers 2021 Dec 13 24
- Ribosome ADP-ribosylation inhibits translation and maintains proteostasis in cancers.
  Challa S, Khulpateea BR, Nandu T, Camacho CV, Ryu KW, Chen H, Peng Y, Lea JS, Kraus WL, Cell 2021 Jul
- HER2 Positive and HER2 Negative Classical Type Invasive Lobular Carcinomas: Comparison of Clinicopathologic Features.
  He L, Araj E, Peng Y, Current oncology (Toronto, Ont.) 2021 Apr 28 3 1608-1617
- ZHX2 promotes HIF1a oncogenic signaling in triple-negative breast cancer.
  Fang W, Liao C, Shi R, Simon JM, Ptacek TS, Zurlo G, Ye Y, Han L, Fan C, Bao L, Ortiz CL, Lin HR, Manocha U, Luo W, Peng Y, Kim WY, Yang LW, Zhang Q, eLife 2021 10
- Identification of BBOX1 as a Therapeutic Target in Triple-Negative Breast Cancer.
  Liao C, Zhang Y, Fan C, Herring LE, Liu J, Locasale JW, Takada M, Zhou J, Zurlo G, Hu L, Simon JM, Ptacek TS, Andrianov VG, Loza E, Peng Y, Yang H, Perou CM, Zhang Q, Cancer discovery 2020 Jul
- The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer.
  Patel A, Unni N, Peng Y, Cancers 2020 Jul 12 8
- Collision Tumor of Endometrial Large Cell Neuroendocrine Carcinoma and Low-Grade Endometrial Stromal Sarcoma: A Case Report and Review of the Literature.
  Rivera G, Niu S, Chen H, Fahim D, Peng Y, International journal of surgical pathology 2020 Jan 1066896920901764
- CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy.
  Denard B, Jiang S, Peng Y, Ye J BMC cancer 2018 Aug 18 1 813
- Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis.
  Regan Anderson TM, Ma S, Perez Kerkvliet C, Peng Y, Helle TM, Krutilina RI, Raj GV, Cidlowski JA, Ostrander JH, Schwertfeger KL, Seagroves TN, Lange CA Molecular cancer research : MCR 2018 Jul
- Cancer stem cells in triple-negative breast cancer: a potential target and prognostic marker.
  O'Conor CJ, Chen T, González I, Cao D, Peng Y Biomarkers in medicine 2018 Jun
- ZMYND8 acetylation mediates HIF-dependent breast cancer progression and metastasis.
  Chen Y, Zhang B, Bao L, Jin L, Yang M, Peng Y, Kumar A, Wang JE, Wang C, Zou X, Xing C, Wang Y, Luo W The Journal of clinical investigation 2018 May 128 5 1937-1955
- Prognostic Role of Tumoral PDL1 Expression and Peritumoral FoxP3+ Lymphocytes in Vulvar Melanomas.
  Chlopik A, Selim MA, Peng Y, Wu CL, Tell-Marti G, Paral KM, Shalin SC, Kraft S, Hsu CK, Shea CR, Puig S, Fernandez-Figueras MT, Biernat W, Rys J, Marszalek A, Hoang MP Human pathology 2018 Jan
- Diagnostic Utility of SATB2 in Metastatic Krukenberg Tumors of the Ovary: An Immunohistochemical Study of 70 Cases With Comparison to CDX2, CK7, CK20, Chromogranin, and Synaptophysin.
  Yang C, Sun L, Zhang L, Zhou L, Zhao M, Peng Y, Niu D, Li Z, Huang X, Kang Q, Jia L, Lai J, Cao D The American journal of surgical pathology 2017 Sep
- Nuclear receptor NR4A1 is a tumor suppressor down-regulated in triple-negative breast cancer.
  Wu H, Bi J, Peng Y, Huo L, Yu X, Yang Z, Zhou Y, Qin L, Xu Y, Liao L, Xie Y, Conneely OM, Jonkers J, Xu J Oncotarget 2017 Aug 8 33 54364-54377
- KIT Mutations and CD117 Overexpression Are Markers of Better Progression-Free Survival in Vulvar Melanomas.
  Dias-Santagata D, Selim MA, Su Y, Peng Y, Vollmer R, Chlopik A, Marti GT, Paral K, Shalin S, Shea CR, Puig S, Fernandez-Figueras MT, Biernat W, Rys J, Marszalek A, Hoang MP The British journal of dermatology 2017 Jul
- Update on Immunohistochemical Analysis in Breast Lesions.
  Peng Y, Butt YM, Chen B, Zhang X, Tang P Archives of pathology & laboratory medicine 2017 Jun
- Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells.
  Krishnan SR, Nair BC, Sareddy GR, Roy SS, Natarajan M, Suzuki T, Peng Y, Raj G, Vadlamudi RK Breast cancer research and treatment 2015 Mar
- Quantification of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry Using the Ventana Image Analysis System: Correlation With Gene Amplification by Fluorescence In Situ Hybridization: The Importance of Instrument Validation for Achieving High (>95%) Concordance Rate.
  Dennis J, Parsa R, Chau D, Koduru P, Peng Y, Fang Y, Sarode VR The American journal of surgical pathology 2015 Jan
- Significantly increased PELP1 protein expression in primary and metastatic triple-negative breast carcinoma (TNBC): comparison with GATA3 expression and PELP1's potential role in TNBC
  Dang D, Raj G, Sarode V, Molberg K, Vadlamudi R and Peng Y* Human Pathology 2015 46 12 1829-1835
- KIF14 Promotes AKT Phosphorylation and Contributes to Chemoresistance in Triple-Negative Breast Cancer.
  Singel SM, Cornelius C, Zaganjor E, Batten K, Sarode VR, Buckley DL, Peng Y, John GB, Li HC, Sadeghi N, Wright WE, Lum L, Corson TW, Shay JW Neoplasia (New York, N.Y.) 2014 Mar 16 3 247-256.e2
- Cutaneous and mammary apocrine carcinomas have different immunoprofiles.
  Piris A, Peng Y, Boussahmain C, Essary LR, Gudewicz TM, Hoang MP Human pathology 2014 Feb 45 2 320-6
- Modulatory effect of neoadjuvant chemotherapy on biomarkers expression; assessment by digital image analysis and relationship to residual cancer burden in patients with invasive breast cancer.
  Cockburn A, Yan J, Rahardja D, Euhus D, Peng Y, Fang Y, Rumnong Sarode V Human pathology 2014 Feb 45 2 249-58
- Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes.
  Daniel AR, Gaviglio AL, Knutson TP, Ostrander JH, D'Assoro AB, Ravindranathan P, Peng Y, Raj GV, Yee D, Lange CA Oncogene 2014 Jan
- Ki-67 expression is increased in p16-expressing triple-negative breast carcinoma and correlates with p16 only in p53-negative tumors.
  Sugianto J, Sarode V, Peng Y Human pathology 2013 Dec
- Roles of p53 and p16 in Triple-negative Breast Cancer (This article was selected to be featured on Oncology Central.)
  Dang D and Peng Y Breast Cancer Management (Future Medicine). 2013 2 6 537-544
- Presence of the sarcomatous component outside the ovary is an adverse prognostic factor for primary ovarian malignant mixed mesodermal/mullerian tumors: a clinicopathologic study of 47 cases.
  Kunkel J, Peng Y, Tao Y, Krigman H, and Cao D. Am. J Surg. Pathol. 2012 36(6) 831-7
- Decreased Androgen Receptor Expression is Associated with Distant Metastases in Patients with Androgen Receptor Expressing Triple-negative Breast Carcinoma.
  Sutton LM, Cao D, Sarode VR, Molberg KH, Torgbe K, Haley B and Peng Y. Am. J Clin. Pathol. 2012 138 511-516 (CME/SAM article)
- Potential prognostic tumor biomarkers in triple negative breast carcinoma. Journal of Peking University (Health Sciences).
  Peng Y. 2012 44 735-741(English)
- Unusual Presentation of Multiple Fibroadenomas in Bilateral Breasts and Axillary Accessory Breast.
  Zhang R, Bevan S, Sun P, Lu JZ and Peng Y. Breast Cancer: Basic and Clinical Research 2012 6 95-99
- Hormone receptor status rather than HER2 status is significantly associated with increased Ki-67 and p53 expression in triple-negative breast carcinomas, and high expression of Ki-67 but not p53 is significantly associated with axillary nodal metastasis in triple-negative and high-grade non-triple-negative breast carcinomas.
  Han JS, Cao D, Molberg KH, Sarode VR, Rao R, Sutton LM, Peng Y American journal of clinical pathology 2011 Feb 135 2 230-7
- Diagnostic utility of RNA-binding protein LIN28 in primitive ovarian germ cell tumors.
  Xue D, Peng Y, Wang F, Allan RW and Cao D Histopathology 2011 3 59 452-459
- Atypical Endosalpingiosis in Axillary Sentinel Lymph Node: A potential Source of False Positive Diagnosis of Metastasis.
  Sarode VR, Euhus D, Thompson M and Peng Y The Breast Journal 2011 6 17 672-673
- A Comparative Analysis of Biomarker Expression and Molecular Subtypes of Pure Ductal Carcinoma In Situ and Invasive Breast Carcinoma by Image Analysis: Relationship of the Subtypes with Histologic Grade, Ki67, p53 Overexpression, and DNA Ploidy.
  Sarode VR, Han JS, Morris DH, Peng Y, Rao R International journal of breast cancer 2011 2011 217060
- Multicentric adenomyoepithelioma of the breast with atypia and associated ductal carcinoma in situ.
  Han JS, Peng Y The breast journal 2010 Sep-Oct 16 5 547-9
- Intratumoral Expression Level of Epidermal Growth Factor Receptor and Cytokeratin 5/6 is Significantly Associated with Nodal and Distant Metastases in Patients with Basal-like Triple-negative Breast Carcinoma.
  Sutton LM, Han JS, Molberg KH, Sarode VR, Cao D and Peng Y. American Journal of Clinical Pathology 2010 134 782-787
- Spontaneous Hematoma of the Breast: Thirty Years after Augmentation.
  Rasko Y, Saint-Cyr M, Peng Y and Rao R Plast. Reconstr. Surg. 2010 1 126 41e-42e
- AlloDerm vs. DermaMatrix in Immediate Expander-based Breast Reconstruction: A Comparative Analysis.
  Becker S, Saint-Cyr M, Wong C, Dauwe P, Nagarkar P and Peng Y 2009 1 123 1-6
- SALL4 is a Novel Sensitive and Specific Marker for Ovarian Primitive Germ Cell Tumors and is Particularly Useful in Distinguishing Yolk Sac Tumor from Clear Cell Carcinoma.
  Cao D, Guo S, Allan RW, Molberg KH and Peng Y American Journal of Surgical Pathology 2009 6 33 894-904
- A Meta-analysis of Comparing Fine Needle Aspiration and Frozen Section for Evaluating Thyroid Nodules.
  Peng Y and Wang HH Diagnostic Cytopathology 2008 36 916-920
- False Positive Sentinel Lymph Nodes in Breast Cancer Patients Caused by Benign Glandular Inclusions.
  Peng Y, Ashfaq R, Ewing G, Leitch AM and Molberg KH American Journal of Clinical Pathology 2008 130 21-27
- Molecular alterations in columnar cell lesions of the breast.
  Dabbs DJ, Carter G, Fudge M, Peng Y, Swalsky P and Finkelstein S 2006 19 344-349
- Impact of reflex HPV testing on interpretation and management of Thinprep Pap tests.
  Peng Y and Wang HH Diagnostic Cytopathology 2006 34 585-588
- ETB receptor activation causes exocytic insertion of NHE3 in OKP cells.
  Peng Y, Amemiya M, Yang X, Fan L, Moe OW, Yin H, Preisig PA, Yanagisawa M and Alpern RJ 2001 280 F34-42.
- Glucocorticoids enhance acid activation of the Na+/H+ exchanger 3 (NHE3).
  Ambuhl PM, Yang X, Peng Y, Moe OW, Preisig PA and Alpern RJ 1999 103 429-435
- ETB receptor activation leads to activation and phosphorylation of NHE3.
  Peng Y, Moe O, Chu T-S, Preisig P, Yanagisawa M and Alpern RJ 1999 276 C938-945
- Reversal of antinatriuretic effect of prostaglandin E2 by verapamil in the rat.
  Peng Y, Ramsey CR and Knox FG Kidney and Blood Pressure Research 1996 19 115-120
- Endothelin B receptor activates NHE3 by a Ca2+-dependent pathway in OKP cell.
  Chu T, Peng Y, Cano A, Yanagisawa M and Alpern RJ 1996 97 1454-1462
- Comparison of systemic and direct intrarenal angiotensin II blockade on sodium excretion in rats.
  Peng Y and Knox FG 1995 269 F40-46

Research

Breast Cancer and Gynecologic Cancer Pathology
Prognostic and predictive tumor biomarkers
Diagnostic Immunohistochemistry: Theranostic and Genomic Applications

Clinical Focus

Breast Pathology
Gynecologic Pathology